Voriconazole: In the treatment of invasive aspergillosis

Drugs

Volumn 62, Issue 18, 2002, Pages 2655-2664

  Muijsers, Richard B R ^a   Goa, Karen L ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; MYCOPHENOLIC ACID; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; PREDNISOLONE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

ADULT; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FUNGUS GROWTH; HUMAN; NONHUMAN; PHOTOPHOBIA; PHOTOSENSITIVITY DISORDER; RASH; RAT; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VISUAL DISORDER; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; INJECTIONS, INTRAVENOUS; PYRIMIDINES; TRIAZOLES;

ASPERGILLUS FUMIGATUS; FUNGI; VINCA;

EID: 0036957299     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262180-00010     Document Type: Review

References (53)

1. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5 (2): 120-35
2. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999 Jan; 12 (1): 40-79
3. Sanati H, Belanger P, Fratti R, et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997; 41 (11): 2492-6
4. National Committee Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibillity testing of conidium forming filamentous fungi: proposed standard. NCCLS document M38-P. Wayne (PA):, 1998
5. Warnock DW, Arthington-Skagg BA, Li R-K. Antifungal drug susceptibility testing and resistance in Aspergillus. Drug Resistance Updates 1999; 2 (5): 326-34
6. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibillities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-8
7. Maesaki S, Iwakawa J, Higashiyama Y, et al. Antifungal activity of new triazole, voriconazole (UK-109,496), against clinical isoaltes of Aspergillus spp. Journal of Infection and Chemotherapy 2000; 6: 101-3
8. Cuenca-Estrella M, Rodriguez-Tudella JL Mellado E, et al. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42 (4): 531-3
9. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001; 45: 605-7
10. Clancy CJ, Nguyen MH. In vitro efficacy antifungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17 (18): 573-5
11. Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998: 42 (1): 91-4
12. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report of from SENTRY Antimicrobial Surveillance Program 2000. Antimicrob Agents Chemother 2002; 46: 1032-7
13. Abraham OC, Manavathu EK, Cutright JL. et al. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999; 33 (1): 7-11
14. Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999: 37 (7): 2343-5
15. Murphy M, Bernard EM, Ishimaru T, et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997 Mar; 41 (3): 696-8
16. Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44 (10): 2865-8
17. George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996: 40 (1): 86-91
18. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41 (1): 13-6
19. Purkins L, Wood N, Ghadramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46 (8): 2546-53
20. Tan K. Clinical pharmacokinetics of a new azole: voriconazole. Clin Microbiol Infect 1999; 5 Suppl. 3: 6
21. Patterson BE, Coates PE. UK- 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract no. F78]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17-20: San Francisco, California; 126
22. Pfizer Inc. VFend (voriconazole): annotated package insert (US). 2002; 1-43
23. Walsh TJ, Wood N, Milligan P, et al. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Illinois
24. Ghahramani P, Purkins L, Allen MJ. The pharmacokinetics and safety of oral voriconazole: a novel broad-spectrum antifungal agent [abstract]. Clin Microbiol Infect 2000; 6 Suppl. 1: 201
25. Ghahramani P, Purkins L, Nichols DJ. Two single-blinded, placebo-controlled studies on the pharmacokinetics of intravenous voriconazole - a novel broad-spectrum antifungal agent [abstract]. Clin Microbiol Infect 2000: 6 Suppl. 1: 201
26. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transplant Infectious Disease 2000; 2 (3): 140-4
27. Blummer JL, Yanovitch S, Schlamm H, et al. Pharmacokinetics and safety of oral voriconazole in patients at risk of fungal infections: a dose escalation study [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 Dec 16-19; Chicago, Illinois
28. Patterson BE, Roffey S, Jezequel SG, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17-20; San Francisco, California: 126
29. Tan K, Wood N, Weil A, et al. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Illinois
30. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal suscesptibillity test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000: 44 (8): 2081-5
31. Ghahramani P, Romero A J, Lant AF, et al. The effect of voriconazole on the pharmacokinetics of cyclosporin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada; 24
32. Ghahramani P, Purkins L, Love ER, et al. Drug interactions between voriconazole and phenytoin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17; Toronto, Canada; 24
33. Wood N, Tan K, Allan R, et al. Effect of voriconazole on the pharmacokinetics of omeprazole [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19: Chicago, Illinois
34. Ghahramani P, Purkins L. Kleinermans DJ. et al. Effect of omeprazole on the pharmacokinetics of voriconazole [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada; 23
35. Wood n, Tan K, Allan R, et al. Effect of voriconazole on the pharmacokinetics of tacrolimus [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Illinois
36. Ghahramani P, Purkins L, Kleinermans D, et al. Voriconazole potentiates warfarin-induced prolongation of prothrombin time [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada; 24
37. Ghahramani P, Purkins L, Kleinermans D, et al. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada: 23
38. Ghahramani P, Purkins L, Kleinermans D, et al. Voriconazole does not affect the pharmacokinetics of digoxin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada; 25
39. Ghahramani P, Purkins L, Kleinermans D, et al. No significant pharmacokinetic interactions between voriconazole and indinavir. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000 Sep 17-20; Toronto, Canada; 24
40. Abel S, Bygrave E, Fielding A, et al. Voriconazole does not affect the pharmocokinetics of mycophenolic acid [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 Dec 16-19; Chicago, Illinois
41. Herbrecht R, Denning DW, Patterson TF. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 (6): 408-15
42. De Pauw B. Clinical potential and experience of voriconazole [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 7
43. Schlamm HT, Corey L, Brown J, et al. Voriconazole for salvage treatment of invasive aspergillosis [abstract]. Clin Infect Dis 2000 Jul; 31: 265
44. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71
45. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21 (3): 240-8
46. Dupont B, Denning D, Lode H. et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 Sep 17-20; San Francisco, California; 127
47. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97 (3): 663-5
48. Van't-Hek LG, Verweij PE, Weemaes CM, et al. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157 (5): 1694-6
49. De Sévaux RGL, Kullberg B J, Verweij PE, et al. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. Clin Infect Dis 1998; 26 (4): 996-7
50. Bielorai B, Toren A, Wolach B, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant 2000 Nov; 26 (9): 1025-8
51. Denning DW. Griffiths CEM. Muco-cutaneous retinoid effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26: 648-53
52. Tan KKC. Brayshaw N, Oakes M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials [abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago, Illinois
53. Pfizer Limited (UK). Vfend 50mg and 200mg film-coated tablets and 200mg powder for solution for infusion [online]. Available from URL: http://emc.vhn.net/eMC/ [Accessed 2002 Nov 12]